| June 2011: |
Updated Aranesp® (darbepoetin alpha) and EPOGEN®/PROCRIT® (epoetin alpha) United States Prescribing information (USPI) for patients with chronic kidney disease (CKD) |
| December 2009: |
Aranesp® (darbepoetin alfa) and EPOGEN®/PROCRIT® (epoetin alfa) Label Change based on TREAT Results Showing an Increased Risk of Stroke in Chronic Renal Failure Patients Not on Dialysis with Anemia and Type 2 Diabetes Treated to a Hemoglobin of 13 g/dL |
| April 2009: |
Reports of antibody-mediated pure red cell aplasia and transfusion-dependent anemia in patients with Hepatitis C virus (HCV) infection treated with ribavirin and interferon or pegylated interferon and an erythropoiesis-stimulating agent (ESA) concurrently |
| August 2008: |
Strengthened Oncology Safety Information and New Medication Guide and Patient Instructions for Use for EPOGEN®/PROCRIT® and Aranesp® |
| March 2008: |
Additional Trials Showing Increased Mortality and/or Tumor Progression with EPOGEN®/PROCRIT® and Aranesp® |
| November 2007: |
Increased Mortality, Serious Cardiovascular and Thromboembolic Events, and Tumor Progression with EPOGEN®/PROCRIT® and Aranesp® |
| March 2007: |
IMPORTANT DRUG WARNING and NEW PRESCRIBING INFORMATION |
